EVALUATION OF EFFECT OF ROFLUMILAST ON BLOOD GLUCOSE LEVELS IN STREPTOZOTOCIN INDUCED DIABETIC ALBINO WISTAR RATS

Objective: To Evaluate hypoglycemic effect of Roflumilast in streptozotocin induced diabetic albino wistar rats. Materials and Methods: 18 albino rats were divided into 3 groups each group containing 6 animals, Group-1 (Diabetic Control): Distilled water 10ml, Group-2 (Standard): Glibenclamide 1.35mg, Group-3 (Test): Roflumilast 0.045mg/kg. A freshly prepared solution of Streptozotocin (45mg/kg body weight) in 0.1ml citrate buffer, pH 4.5 was injected intraperitoneally in a volume of 1ml/kg body weight to overnight fasted rats. After 48 hours of STZ administration, rats with moderate diabetes were selected for the experiment. A base line Capillary Blood Glucose was checked just before giving streptozotocin. All along the course of study animals were provided with water and food ad libitum. On the 3rd day animals were evaluated for the diabetic status by checking CBG. Only diabetic rats were used for further study. They were given above drugs for a period of 28 days starting from 3rd day after giving streptozotocin. Blood glucose levels and body weight were measured on 0, 7^th, 14^th, 21^st and 28^th days. Result: Roflumilast has significant and sustained oral hypoglycemic activity in streptozotocin induced diabetic rats compared to diabetic control group, and also being statistically significant and comparable to the hypoglycemic effect of glibenclamide. Conclusion: These findings suggest that the hypoglycemic potential of the test compound Roflumilast is promising and found to be more significant than the diabetic control group.